Sanofi and Novo Nordisk, 2 of the 3 major insulin makers that dominate the global market, have raised the prices of their medications in the U.S. by at least 4%, depending on the particular insulin, the Financial Times reports.
The big picture: The companies say the hikes cover rebates paid to middlemen. Eli Lilly, the third major manufacturer, has not raised the price of its insulin products and did not immediately comment to Axios about whether it planned to do so this year.
Go deeper: The outrage over insulin prices
